Emerging Company in the Spotlight sponsored by JFK Communications.
BioNJ is pleased to shine the spotlight on one of our Innovation Members each month featuring their progress and work on behalf of Patients and their impact on the New Jersey life sciences ecosystem. This month’s Emerging Company in the Spotlight is Admera Health.
So many of our Members are making a dramatic impact on our State’s innovation ecosystem. We celebrate you! Admera Health is one such company.
Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing clinical services. Headquartered in South Plainfield, NJ, Admera is redefining disease screening, diagnosis, prognosis, treatment, monitoring, and management through its use of next generation technology platforms and advanced bioinformatics.
Admera’s mission is to deliver transformative, valuable solutions for patients, physicians, integrated health delivery networks, hospitals and clinical researchers. Admera is committed to improving the health and well-being of the global community through the direct delivery of personalized, medically actionable results.
After a successful career in drug development for GSK and Merck, Guanghui Hu, PhD, co-founded Admera with a mission to personalize the treatment process for each individual patient. With advancements in sequencing technology, Admera can provide comprehensive testing services that span the continuum of patient care. The affordability of human genome sequencing enables the application of genomics to personalize human disease diagnosis, treatment and monitoring. This spawned his vision to establish Admera as the preeminent precision medicine service laboratory in the world.
“My passion and mission is to exploit the human genome to enable personalized medicine solutions,” Dr. Hu says. “Using genetic information and genome technology, we aim to discover ways to deliver the right dose to the right patient at the right time.”
Admera’s business strategy and foundational core focuses on the three areas of highest unmet need and leading causes of death: cardiovascular disease, cancer, and adverse events/drug interactions. Through Next Generation Sequencing (NGS) and propriety bioinformatics, Admera’s pharmacogenomics test (PGxOne™ Plus) provides treatment recommendations based on a patient’s individual DNA. Results include drugs to avoid, dosing recommendations, which drugs should be prescribed with caution, and what drugs should provide a normal response.
Admera’s current product portfolio consists of the following NGS based tests:
- PGxOne™ Plus
- Cardiovascular Test Portfolio
In addition to its current portfolio, Admera is developing several non-invasive cancer tests to reduce the need for invasive biopsies and tissue collection. These tests collect circulating tumor DNA from blood and are designed for early disease detection, treatment guidance, treatment response monitoring, and disease recurrence monitoring.
Admera also plans to launch a digital automatic system, “Actionable Genomic Interpretation System” or AGIS™, designed to provide end-to-end data analysis and interpretation solutions from raw sequencing data to clinically actionable reports. The AGIS™ system modules include personalized and actionable recommendations in the areas of pharmacogenomics, disease risk, inherited disease and nutrigenomics.
Admera’s Biopharma solutions partners with companies to develop companion diagnostics and novel drugs. Admera’s Biopharma solutions also drives innovation around clinical biomarkers, RUO reagent kits, genomics and bioinformatics. Admera anticipates that this part of their business will complement their existing pipeline and lead to additional product development.
The Next Five Years
Admera is building its future on innovation and the translation of evolving technology into solutions for patients, physicians and partner life science companies. This was illustrated in its recent Frost & Sullivan award for technology and innovation. While most service laboratories have transitioned away from performing their own research and development, Admera has robust R&D capabilities and believes this is key to maximizing technology for the ultimate benefit for patients.
Admera is working to provide cost-effective solutions to improve precision medicine while growing and providing career opportunities in New Jersey. Admera is a vibrant component of New Jersey’s rich and vital biotechnology ecosystem and is excited about its future growth using advanced diagnostic and digital health technologies and partnering with other regional and global life science leaders.
For more information about Admera, please visit: www.admerahealth.com.